5-Fluoro-1-methoxy-2,3-dimethylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-Fluoro-1-methoxy-2,3-dimethylbenzene
• 英文别名: 5-fluoro-1-methoxy-2,3-dimethylbenzene
• 化学式: C₉H₁₁FO
• 分子量: 154.18
• InChiKey: GHMROWFWYDPHBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：GILEAD CALISTOGA LLC

  公开号：US20140179718A1

  公开（公告）日：2014-06-26

  The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R 1 , R 2 , and R 3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

  本披露提供了公式（I）的磷脂酰肌醇3-激酶（PI3K）抑制剂，或其药学上可接受的盐，其中n，m，R1，R2和R3如本文所定义。这些化合物对于治疗由一个或多个PI3K亚型介导的疾病非常有用，如PI3Kδ。本披露进一步提供了包括公式（I）的化合物或其药学上可接受的盐的制药组合物，并使用这些化合物和组合物的方法来治疗由一个或多个PI3K亚型介导的疾病，如PI3Kδ。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3798214A1

  公开（公告）日：2021-03-31

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明的特征是一种式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、W、X、Y、Z、n、o、p 和 q 在本文中定义，用于治疗 CFTR 介导的疾病，如囊性纤维化。本发明还包括药物组合物、治疗方法及其试剂盒。
• ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Calistoga LLC

  公开号：EP2935246B1

  公开（公告）日：2018-07-25
• US9029384B2
  申请人：——

  公开号：US9029384B2

  公开（公告）日：2015-05-12
• [EN] ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS<br/>[FR] INHIBITEURS D'ISOQUINOLINONE PHOSPHATIDYLINOSITOL 3-KINASE OU DE QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：GILEAD CALISTOGA LLC

  公开号：WO2014100767A1

  公开（公告）日：2014-06-26

  The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which n, m, R1, R2, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more P13K isoforms, such as PI3K8. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.